Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group has announced successful results from its Phase III trial of Ameile, an innovative drug designed to treat EGFR-mutated non-small cell lung cancer, in combination with chemotherapy. The trial demonstrated a significant improvement in progression-free survival for patients, marking an important milestone for the company. Detailed results are set to be presented at an upcoming medical conference.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.